Loss of RasGAP tumor suppressors underlies the aggressive nature of luminal B breast cancers

Cancer Discovery

Volumn 7, Issue 2, 2017, Pages 202-217

  Olsen, Sarah Naomi ^a,b   Wronski, Ania ^c,d   Castaño, Zafira ^a,b,e,f   Dake, Benjamin ^c,d   Malone, Clare ^a,b   De Raedt, Thomas ^a,b   Enos, Miriam ^a,b   Derose, Yoko S ^h   Zhou, Wenhui ^c,d   Guerra, Stephanie ^a,b   Loda, Massimo ^g   Welm, Alana ^h   Partridge, Ann H ^b,g   McAllister, Sandra S ^a,b,e,f   Kuperwasser, Charlotte ^c,d   Cichowski, Karen ^a,b,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f HARVARD STEM CELL INSTITUTE   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN DAB2IP; TUMOR SUPPRESSOR PROTEIN RASAL2; UNCLASSIFIED DRUG; CARRIER PROTEIN; DAB2IP PROTEIN, HUMAN; PROTEIN P21; RASAL2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DISEASE COURSE; GENETICS; MCF-7 CELL LINE; METABOLISM; METASTASIS; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MCF-7 CELLS; MICE; MUTATION; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PROTO-ONCOGENE PROTEINS P21(RAS); RAS GTPASE-ACTIVATING PROTEINS; SIGNAL TRANSDUCTION;

EID: 85011890621     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0520     Document Type: Article

References (42)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer J Clin 2016; 66: 7-30.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease: A view of metastasis. J Intern Med 2013; 274: 113-26.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
4. Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100: 10393-8.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
6. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A Comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-32.
7. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
8. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011; 13: 221.
9. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013; 3: 27-34.
10. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
11. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
12. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 2004; 91: 355-8.
13. Gao J, Aksoy BA, Dogrusoz U, Dresdner G. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 269: p11.
14. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
15. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997; 99: 1478-83.
16. Lintig von FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat 2000; 62: 51-62.
17. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 384-8.
18. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003; 1603: 47-82.
19. Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regul 2014; 55: 1-14.
20. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nat Med 2010; 16: 286-94.
21. McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, Bronson RT, et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 2013; 24: 365-78.
22. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-27.
23. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 2013; 142: 237-55.
24. Subik K, Lee JF, Baxter L, Strzepek T. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl.) 2010; 4: 35-41.
25. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011; 13: 215.
26. Collins LC, Gelber S, Marotti JD, White S, Ruddy K, Brachtel EF, et al. Molecular phenotype of breast cancer according to time since last pregnancy in a large cohort of young women. Oncologist 2015; 20: 713-8.
27. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-64.
28. Campbell MJ, Wollish WS, Lobo M, Esserman LJ. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell Dev Biol Anim 2002; 38: 326-33.
29. Shin S, Dimitri CA, Yoon S-O, Dowdle W, Blenis J. ERK2 but Not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38: 114-27.
30. Virtakoivu R, Pellinen T, Rantala JK, Perala M, Ivaska J. Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell 2012; 23: 3357-69.
31. Chin YR, Toker A. Akt isoform-specific signaling in breast cancer. Cell Adh Migr 2014; 5: 211-4.
32. Zhang H. AIP1/DAB2IP, a novel member of the ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J Biol Chem 2004; 279: 44955-65.
33. Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS. Oncogenic PI3K mutations lead to NF-B-dependent cytokine expression following growth factor deprivation. Cancer Res 2012; 72: 3260-9.
34. Dhawan P, Richmond A. A Novel NF-B-inducing Kinase-MAPK signaling pathway up-regulates NF-B Activity in melanoma cells. J Biol Chem 2002; 277: 7920-8.
35. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-79.
36. Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y, et al. Nuclear factor-κB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep 2014; 4: 1-8.
37. DeRose YS, Wang G, Lin Y-C, Bernard PS, Buys SS, Ebbert MTW, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17: 1514-20.
38. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, et al. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res 2014; 74: 1463-74.
39. Zhu J, Sanborn JZ, Benz SC, Craft B, Szeto C. The UCSC Cancer Genomics Browser. Nat Methods 2009; 6: 239-40.
40. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2009; 123: 725-31.
41. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in threedimensional basement membrane cultures. Methods 2003; 30: 256-68.
42. Li L-C, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002; 18: 1427-31.